Pre-eclampsia appears to be the main cause for the maternal and fetal morbidity and mortality.
Pregnant women with pre-eclampsia are more likely to be threatened with conditions which potentially
may be lethal, such as: disseminated intravascular coagulation, cerebral hemorrhage, liver and
renal failure. Pregnancy complicated with pre-eclampsia is also associated with a greater risk for iatrogenic prematurity,
intrauterine growth retardation, premature abruption of placenta, and even intrauterine fetal death. In the majority of cases
the reasons for arterial hypertension among pregnant women remain obscure. For the past decades, there were many abortive
attempts in the use of some microelements, vitamins or specific diets, such as polyunsaturated fatty acids, for the prophylaxis
of pre-eclampsia. Recently, it has been shown that a prevention of pre-eclampsia with the use of a lowmolecular-
weight heparins (LMWHs) and acetylsalicylic acid (ASA) could considerably reduce the frequency of preeclampsia.
In this review, we present the studies concerning the applications of LMWHs and aspirin in the prophylaxis of
pre-eclampsia and some important data about the mechanisms of anti-inflammatory actions of LMWHs and ASA.